The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY
Published in New England Journal of Medicine
Methodology
SOTI: randomized, double-blind, placebo-controlled trial of strontium ranelate 2 g/day in 1,649 postmenopausal women with vertebral osteoporosis over 3 years.
Key Findings
New vertebral fractures were reduced by 41% versus placebo, with significant increases in lumbar BMD.
Conclusions
Strontium ranelate reduces vertebral fracture risk in postmenopausal osteoporosis.
Limitations
BMD gains partly reflect strontium's atomic weight; results apply to the ranelate salt, not dietary strontium.
Supplements Studied
Strontium ranelate reduces vertebral fracture risk in postmenopausal osteoporosis.
Outcomes Measured
New vertebral fractures were reduced by 41% versus placebo, with significant increases in lumbar BMD.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.